This review highlights the pathophysiology of functional tricuspid regurgitation in mitral valve disease and discusses the evolving role of transcatheter therapies as alternatives to surgery.
Indications and timing for surgery in functional TR remain debated; leaves open need for prospective trials to guide practice.
Functional tricuspid regurgitation is a common finding in patients with left-sided heart disease. If left untreated, it may reduce survival, limit functional capacity and cause end-organ dysfunction. Annulus dilation and leaflet tethering due to right ventricle remodeling are 2 major pathophysiologic mechanisms in functional tricuspid regurgitation. Even if surgical treatment remains the gold standard, indication and timing of surgical interventions remain the object of debate in the medical community. More recently, numerous transcatheter therapies have been developed in order to offer less invasive options to patients who otherwise would have a high risk of mortality and morbidity with surgical interventions.
No takes yet. Share an insight, caveat, or question.
McCartney et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: